 |
Scott
J. Antonia, M.D., Ph.D. Member-in-Residence of the Moffitt Cancer Center E-mail:
Scott.Antonia@moffitt.org |
Training
B.S., University of Connecticut, Biology 1982
Ph.D., University of Connecticut Health Center, Immunology 1987 M.D.,
University of Connecticut Health Center 1989
Internal Medicine Resident, Yale-New Haven Hospital 1989-1991 Medical
Oncology Fellow, Yale School of Medicine 1991-1994
Post-doctoral Fellow, Section of Immunobiology, Yale School of Medicine
1992-1996
Associate Research Scientist, Yale School of Medicine 1994
Research
Interests
Dr. Antonia directs a translational research program that has the overall
goal of developing novel immunotherapeutic strategies for the treatment
of cancer patients. The basic research component of the program is to
perform preclinical proof-of-principle testing of new vaccines, and to
determine the mechanisms by which the tumor microenvironment is hostile
to T cells. The vaccines currently under development are a GM-CSF/CD40
ligand gene-modified tumor cell vaccine, and dendritic cell based vaccines.
With respect to the study of the tumor microenvironment, indoleamine 2,3-dioxygenase
(IDO) has been identified as a significant immunosuppressive enzyme produced
by tumor cells. A competitive inhibitor of IDO is currently being developed
as a tumor vaccine augmentation strategy. Optimization and safety testing
of the vaccines and augmentation strategies in anticipation of FDA IND
applications is also performed.
The clinical research component of the translational research program involves the testing of the vaccines and augmentation strategies in cancer patients. An infrastructure has been put into place to accomplish this. A diverse group of investigators at the H. Lee Moffitt Cancer Center needed to accomplish these logistically complex clinical trials has been formed, and a vaccine production facility that operates with standard operating procedures compliant with current good manufacturing practices is operational. A phase I B7-1 gene-modified autologous tumor cell vaccine trial involving patients with metastatic renal cell carcinoma has been completed, and the phase II trial in ongoing.
Search
for publications by: 
This
search will be conducted at the US National Library of Medicine (NLM) and PubMed.
Selected
Publications
Antonia, S.J., Geiger, T., Miller, J., and Flavell, R.A. 1995. Mechanisms
of immune tolerance induction through the thymic expression of a peripheral
tissue-specific protein. Int. Immunol. 7:715-725.
Antonia, S.J., Muņoz-Antonia, T., Soldevila, G., Miller, J., and Flavell, R.A. 1995. B7-1 Expression by a non-antigen presenting cell-derived tumor. Cancer Research 55:2253-2256.
Antonia, S.J., Wagner, H., Williams, C., Alberts, M., Hubbel, D., Robinson, L., Hilstro, J., and Ruckdeschel, J. 1996. Concurrent paclitaxel and cisplatin with thoracic radiation in patients with stage III A/B non-small cell carcinoma of the lung. Seminars in Oncology 22:34-37.
Garrigue-Antar, L., Muņoz-Antonia, T., Antonia, S.J., Gesmonde, J., Velluci, V.F., and Reiss, M. 1996. Missense mutations of the transforming growth factor-? type II receptor in human head and neck squamous carcinoma cells. Cancer Research 55:3982-3987.
Antonia, S.J., Finley, C., and Muņoz-Antonia, T. 1996. Cloning and partial characterization of the mouse B7-1 promoter. Immunogenetics 43:234-237.
Rabb, H., Ramirez, G., Saba, S.R., Reynolds, D., Xu, J.C., Flavell, R.A., and Antonia, S.J. 1996. Renal ischemic-reperfusion injury in L-selection-deficient mice. Am. J. Physiol. 271:F408-F413.
Muņoz-Antonia, T., Li, X., Reiss, M., and Antonia, S. 1996. A mutation in the TGFB type II receptor gene promoter associated with loss of gene expression. Cancer Res. 56:4831-4835.
Antonia, S.J., and Ruckdeschel, J.C. 1997. Improving our management of non-small-cell lung cancer and mesothelioma. Cancer Control 4:293.
Antonia, S.J., Robinson, L., Ruckdeschel, J., and Wagner, H. 1998. Lung Cancer in "Comprehensive Geriatric Oncology", edited by L. Balducci, G.H. Lyman, and W.B. Ershler, Harwood Academic Publishers.
Garland, L.L., Ruckdeschel, J.C., Wagner, H., Williams, C.C., Shaw, G., Antonia, S.J., Heise, M., Hilstro, J., and Cantor, A. 1998. Single agent paclitaxel as second-line chemotherapy for resistant, metastatic, non-small-cell lung cancer. In "Taxanes in Lung Cancer Therapy", edited by D.H. Johnson and J. Klastersky, Marcel Dekker, Inc.
Antonia, S.J., M. Extermann and R. A. Flavell. Immunologic Nonresponsiveness To Tumors. Critical Reviews in Oncogenesis, 1998. 9:35-41.
Antonia, S.J. 1999. B7-1 gene modified tumor cell vaccines. Current Opinion in Molecular Therapeutics. 1:50-56.
Reintgen, D., Antonia, S.J. 1999. Immunotherapy: The next major advance. Skin Cancer Foundation Journal. 17:41-42.
Jennings, R., Muņoz-Antonia, T., Zhu, Z., Jackson, R., and Antonia, S.J.. 1999. Identification of an enhancer element in the murine B7-1 promoter. Immunogenetics. 50: 109-112.
Jackson, R.J., Antonia, S.J., Moon, N., Ghosh, N., Nepveu, A., and Munoz-Antonia, T. 1999. Human cut-like repressor protein regulates TGF$ Type II receptor gene promoter activity. Arch. Biochem. Biophys. 371: 290-300.
Antonia, S.J. 1999. Tumor cell vaccines for renal cell carcinoma. Cancer Control Journal. 6: 608-611.
Antonia, S.J. and Sotomayor, E. 1999. Gene therapy for lung cancer. Current Opinion in Oncology. 12: 138-142.
Antonia, S.J. 1999. B7-1 gene-modified tumor cell vaccine for renal cell carcinoma. World Journal of Urology. 18: 157-163.
Cancer Biology Ph.D. Program
H. Lee Moffitt Cancer Center, MRC-4 East
12902 Magnolia Drive
Tampa, Florida 33612
Phone: 813-745-6876
E-mail: CancerPHD@moffitt.org
Copyright © 2000 University of South Florida